In The News

In The News

SelectScience Interview | January 29, 2018
Henrik Zetterberg discusses the use of ultrasensitive biomarker assays from Quanterix for Alzheimer’s research
SelectScience Interview | January 29, 2018
Bonnie Howell, Executive Director at Merck, discusses the use of ultrasensitive Quanterix technology to develop novel therapies for HIV and shares her hopes for a future world, free of the disease
TheStreet | January 22, 2018
With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.
GenomeWeb | January 17, 2018
Fresh off a $74 million initial public offering, Quanterix is looking to make immediate inroads in the biotech and pharma research space with longer-term plans to move into diagnostics and health monitoring.
Medical Device and Diagnostic Industry | January 16, 2018
Would you rather get a biopsy or a blood test to check for prostate cancer?
Genetic Engineering & Biotechnology News | January 15, 2018
New technology has shown promise for detecting CTE and the approximately 150 protein biomarkers linked to conditions in neurology, oncology, cardiology, inflammation, and infectious disease. Called Simoa™, it is a single-molecule array on a fully automated digital immunoassay platform that detects…
January 12, 2018
Presentation led by Kevin Hrusovsky, President, Chairman and CEO Quanterix Presentation Date: Wednesday, January 10, 2018  
Bloomberg Baystate Business | December 08, 2017
Bloomberg Boston Bureau Chief Tom Moroney and Radio News Anchor Anne Mostue are joined by Quanterix CEO Kevin Hrusovsky to discuss his company’s IPO and first day of trading
Cheddar.com | December 08, 2017
Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share.
The Wall Street Journal | December 08, 2017
Biomarker-analysis company had raised venture capital from ARCH Venture Partners, Bain